IL-31 / PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS CONTAINING IL-31 ANTAGONIST AS ACTIVE INGREDIENT

摘要

In one non-limiting embodiment, a pharmaceutical composition for preventing and/or treating atopic dermatitis containing an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is 0.1 mg to 1000 mg/body/day ~12 weeks, preferably 0.1mg ~ 1000mg / body / 2 weeks, 0.1mg ~ 1000mg / body / 4 weeks, or 0.1mg ~ 1000mg / body / 8 weeks, atopic dermatitis, or fear of being affected A pharmaceutical composition, which is administered in an equivalent amount and repeatedly at the same administration interval to a subject with